Allergy Shots for Food Allergies: SCIT Is Not Indicated — Here Are the Current Options
URGENT: Allergy shots (SCIT) are NOT the standard of care for IgE-mediated food allergies. Current options are oral immunotherapy (Palforzia, FDA 2020 — COMMERCIALLY DISCONTINUING JULY 31, 2026, approximately 62 days away), Xolair (omalizumab, FDA approved February 16, 2024, OUtMATCH trial 67% vs 7% peanut protection), and off-label OIT through specialized food-allergy clinics. SCIT for food was abandoned after a 1992 fatal peanut SCIT trial (Oppenheimer et al., JACI 1992).
7 peer-reviewed sources
Allergy shots (SCIT) are not indicated for food allergies. The current FDA-approved food-allergy options are Palforzia (peanut OIT, FDA Jan 2020, commercially discontinuing July 31, 2026) and Xolair (omalizumab, FDA Feb 2024, 67% multi-food protection). Off-label OIT continues through specialized clinics.
The essentials
Allergy shots (SCIT) are NOT the standard of care for IgE-mediated food allergies — current options are oral immunotherapy (Palforzia, FDA 2020, discontinuing July 31, 2026), Xolair (FDA Feb 2024), and off-label OIT through specialized food-allergy clinics.
TIME-SENSITIVE NOTICE: Palforzia (peanut allergen powder-dnfp, AR101), the only FDA-approved oral immunotherapy for peanut allergy, is commercially discontinuing effective July 31, 2026 — approximately 62 days from the date this page was generated (May 29, 2026). This is a voluntary commercial decision by Stallergenes Greer and Nestlé Health Science unrelated to safety or efficacy. Patients currently on Palforzia should contact their prescribing allergist immediately to discuss transition options before July 31, 2026.
Subcutaneous food immunotherapy was attempted in the 1990s and abandoned after high systemic-reaction rates and a fatal trial. The seminal citation is Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leung DY (JACI 1992;90:256–262): the peanut SCIT trial demonstrated efficacy signal but a 13.3% systemic reaction rate, was terminated after a fatal anaphylaxis caused by a pharmacy formulation error, and established that the subcutaneous route is too dangerous for routine food allergen immunotherapy. Conventional SCIT formulary — Greer, ALK-Abelló, Stallergenes Greer — excludes food allergens entirely for all FDA-licensed US manufacturers (aeroallergens, venoms, and molds only).
Curex's at-home IgE testing with board-certified allergist review identifies sensitization to both aeroallergens (where SCIT and sublingual immunotherapy are appropriate) and food allergens (where they are not) — distinguishing the two profiles is the necessary precondition for any treatment decision.
The three current evidence-based options for food allergy:
1. Oral immunotherapy (OIT): Palforzia (peanut allergen powder-dnfp, Aimmune Therapeutics → Stallergenes Greer / Nestlé Health Science; FDA approved January 31, 2020) for ages 4–17 (continued beyond 17 once started). Pivotal PALISADE Trial (Vickery BP et al., NEJM 2018;379:1991–2001): 50.3% of treated patients aged 4–17 tolerated 1,000 mg peanut protein at exit challenge versus 2.4% placebo. COMMERCIAL DISCONTINUATION: July 31, 2026. Final new-patient starts: January 30, 2026. Off-label OIT through specialized food-allergy clinics (Mount Sinai, Stanford, Children's Hospital of Philadelphia, and others) continues but is not FDA-regulated.
2. Xolair (omalizumab, Genentech/Novartis): FDA approved February 16, 2024 for reduction of allergic reactions including anaphylaxis from accidental food exposure in patients ≥1 year with IgE-mediated food allergy. Based on the NIH/NIAID-funded OUtMATCH trial (Wood RA et al., NEJM 2024;390:889–899; DOI 10.1056/NEJMoa2312382): 67% of omalizumab-treated participants versus 7% placebo tolerated ≥600 mg peanut protein after 16–20 weeks. OUtMATCH Stage 2 (NIH/NIAID March 3, 2025): 36% on extended omalizumab versus 19% on multi-allergen OIT tolerated ≥2 g peanut plus two other food allergens (OR 2.6, P=.031). Xolair is anti-IgE monoclonal therapy — NOT allergen-specific tolerance induction. It requires ongoing repeated dosing alongside continued food avoidance. Xolair is NOT emergency anaphylaxis treatment — epinephrine remains the rescue medication.
3. Off-label SLIT for food: research stage only, not FDA-approved. Available at select academic centers. Results to date are mixed.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youFrequently asked questions
Can allergy shots treat peanut allergy?
No. Subcutaneous immunotherapy (SCIT) for peanut allergy was attempted in the 1990s and abandoned after unacceptably high systemic reaction rates and a fatal trial (Oppenheimer JJ et al., JACI 1992). The FDA-approved treatment for peanut allergy was Palforzia (oral immunotherapy), approved January 31, 2020 for ages 4–17. Palforzia is commercially discontinuing July 31, 2026. Omalizumab (Xolair) was FDA-approved February 16, 2024 for food-allergy reaction prevention including peanut, with 67% threshold protection versus 7% placebo in the OUtMATCH trial (Wood RA et al., NEJM 2024). Off-label OIT through specialized food-allergy clinics continues after Palforzia's sunset.
What is Palforzia and why is it discontinuing?
Palforzia (peanut allergen powder-dnfp, AR101) is the only FDA-approved oral immunotherapy for peanut allergy, approved January 31, 2020 for initiation in ages 4–17 based on the PALISADE Trial (Vickery BP et al., NEJM 2018;379:1991–2001). The commercial discontinuation effective July 31, 2026 was announced by Stallergenes Greer and Nestlé Health Science as a voluntary business decision — not a safety withdrawal. Approximately 5,000–7,000 US patients were on Palforzia at the time of announcement. Patients currently on Palforzia should contact their allergist before July 31, 2026 to discuss continuation through off-label OIT or transition to Xolair. No FDA-approved peanut OIT successor product is currently available.
What replaced allergy shots for food allergy?
Oral immunotherapy (OIT) replaced subcutaneous food immunotherapy after the 1992 peanut SCIT trial fatality established that the subcutaneous route is too dangerous for food allergens. The only FDA-approved OIT product was Palforzia (peanut, FDA 2020), which is commercially discontinuing July 31, 2026. The current FDA-approved alternative is Xolair (omalizumab), approved February 16, 2024 for food-allergy reaction prevention — anti-IgE monoclonal therapy that reduces anaphylaxis risk from accidental food exposure without inducing allergen-specific tolerance. Off-label OIT through specialized food-allergy clinics (peanut, milk, egg, and other foods) remains available at academic centers.
Is Xolair effective for food allergy?
Yes, with important caveats about what 'effective' means in this context. Xolair (omalizumab) was approved February 16, 2024 for food-allergy reaction prevention, not for curative desensitization. The OUtMATCH trial (Wood RA et al., NEJM 2024;390:889–899) found that 67% of omalizumab-treated participants versus 7% placebo tolerated at least 600 mg peanut protein without dose-limiting symptoms after 16–20 weeks of treatment. This represents meaningful protection against accidental food exposures — not deliberate food challenges. Xolair requires ongoing dosing (every 2–4 weeks subcutaneously) alongside continued food avoidance. It is not a cure, does not produce permanent tolerance, and must not be used as emergency anaphylaxis treatment (epinephrine remains the rescue medication).
I am currently on Palforzia — what should I do before July 31, 2026?
Patients currently on Palforzia should contact their prescribing allergist immediately to discuss transition options before the July 31, 2026 commercial discontinuation. Options typically include: (1) continuing peanut OIT off-label through a specialized food-allergy clinic using a similar protocol but without Palforzia's FDA-regulated product; (2) transitioning to omalizumab (Xolair) for ongoing protection against accidental peanut exposure; or (3) combining off-label OIT with Xolair, which the OUtMATCH Stage 2 data (NIH/NIAID, March 2025) suggests may have additive benefit. Do not stop peanut OIT abruptly without allergist guidance — tolerance achieved through OIT may decay over weeks to months after discontinuation.
Why is SCIT not used for food allergy?
SCIT for food allergy was abandoned after the seminal 1992 peanut SCIT trial (Oppenheimer JJ et al., JACI 1992;90:256–262) demonstrated a 13.3% systemic reaction rate — and was terminated after a fatality caused by a pharmacy formulation error in which a placebo patient received a maintenance peanut dose. A second study (Nelson 1997) confirmed systemic reaction rates of 13.3–39%. The subcutaneous route delivers allergen directly into tissue, producing rapid immune activation that is appropriate for dilute aeroallergen extracts but too dangerous for food allergens at the concentrations required for desensitization. The field concluded that the oral route (OIT) and anti-IgE biologics (Xolair) offer better safety profiles for food-allergy treatment.
Can sublingual drops treat food allergies?
Sublingual immunotherapy for food allergy remains investigational and is not FDA-approved as of May 2026. Research studies at academic centers have explored sublingual peanut, milk, and hazelnut formulations, with some showing partial desensitization but inconsistent efficacy compared to oral OIT. No FDA-approved sublingual product exists for any food allergen; the four FDA-approved SLIT tablets (Grastek, Oralair, Ragwitek, Odactra) are all for aeroallergens (grass, ragweed, house dust mite), not food allergens. The Sampson HA et al. (JACI 2014) food allergy practice parameter does not recommend sublingual immunotherapy as a standard treatment for food allergy.
Related Articles
Allergy Shots for Pollen: Who Qualifies | Curex Guide
Yes, allergy shots target pollen via SCIT. Cox 2011 candidacy threshold, FDA SLIT tablets, per-allergen efficacy, and Curex at-home shots — all covered.
Read moreHow Much Are Allergy Shots – Complete Cost Guide 2026
Medicare $11.97/visit (CPT 95117, CY 2025 PFS); commercial $15–18; cash $40–200+; HOPD up to $24,400. Full build-up, maintenance & 5-year cost breakdown.
Read moreAllergy Shots for Kids: PAT Study & Age Guide | Curex
Allergy shots from age 5. PAT study: 3 yrs SCIT halves asthma risk (OR 4.6). At-home SCIT via Curex for eligible pediatric families.
Read moreFood Allergy Shots: Palforzia Sunset July 2026 | Curex
Food allergy shots (FDA-approved) do not exist. Palforzia peanut OIT ends July 31 2026. Xolair (FDA Feb 2024) is next. Curex: environmental allergies.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.